Alcyomics Ltd, Bulman House, Regent Centre, Gosforth, Newcastle-upon-Tyne NE3 3LS, United Kingdom.
Pfizer Inc., Drug Safety Research and Development, Eastern Point Rd, Groton, CT 06340, USA.
Toxicol Appl Pharmacol. 2019 Apr 15;369:39-48. doi: 10.1016/j.taap.2019.02.005. Epub 2019 Feb 12.
The occurrence of drug hypersensitivity reactions (DHRs) following administration of low molecular weight (LMW) drugs is an important health concern. However, in vivo animal models which could be used as tools for the prediction of DHRs are lacking. As a result, research has focused on development of in vitro tools for predicting DHRs. In this study a novel human in vitro pre-clinical skin explant test was used to predict T cell-mediated hypersensitivity responses induced by LMW drugs. Responses in the skin explant test for 12 LMW drugs associated with T cell-mediated hypersensitivity in the clinic (abacavir, amoxicillin, carbamazepine, diclofenac, lamotrigine, lapatinib, lumiracoxib, nevirapine, ofloxacin, phenytoin, propranolol, sulfamethoxazole) were compared with responses for 5 drugs with few/no reports of T cell-mediated hypersensitivity reactions (acetaminophen, cimetidine, flecainide, metformin, verapamil). Changes in skin histology following in vitro exposure to the drugs as well as T cell proliferation and interferon gamma (IFNγ) production were studied. The results of the skin explant assays showed a good positive correlation (r = 0.77, p < .001) between the test outcome (prediction of positive or negative) and the clinical classification of the tested drugs. The T cell proliferation assay showed a correlation of r = 0.60 (p < .01) and the IFNγ assay r = 0.51 (p < .04). The data suggest that the skin explant model could be a useful tool to predict the potential of LMW drugs to induce DHRs.
低分子量 (LMW) 药物引起的药物超敏反应 (DHR) 的发生是一个重要的健康问题。然而,缺乏可用于预测 DHR 的体内动物模型。因此,研究集中在开发用于预测 DHR 的体外工具上。在这项研究中,使用了一种新型的人类体外临床前皮肤外植体试验来预测 LMW 药物引起的 T 细胞介导的超敏反应。对 12 种与临床 T 细胞介导超敏反应相关的 LMW 药物(阿巴卡韦、阿莫西林、卡马西平、双氯芬酸、拉莫三嗪、拉帕替尼、鲁米昔布、奈韦拉平、氧氟沙星、苯妥英、普萘洛尔、磺胺甲恶唑)的皮肤外植体试验反应与 5 种药物的反应进行了比较,这些药物很少/没有报道 T 细胞介导的超敏反应(对乙酰氨基酚、西咪替丁、氟卡尼、二甲双胍、维拉帕米)。研究了药物体外暴露后皮肤组织学变化以及 T 细胞增殖和干扰素 γ(IFNγ)产生情况。皮肤外植体试验结果显示,试验结果(预测阳性或阴性)与受试药物的临床分类之间存在良好的正相关(r=0.77,p<.001)。T 细胞增殖试验显示相关性 r=0.60(p<.01),IFNγ 试验 r=0.51(p<.04)。数据表明,皮肤外植体模型可能是预测 LMW 药物引起 DHR 潜力的有用工具。